tips and techniques for culturing primary cells

ATCC Primary Cell Culture Guide

TIPS AND TECHNIQUES FOR CULTURING PRIMARY CELLS

Page 2 Order online at www.atcc.org, call 800.638.6597, 703.365.2700, or contact your local distributor.

Table of ContentsATCC® PRIMARY CELL SOLUTIONS® ..............3

Primary cells and cell types .............................................................. 3Basic properties of primary cells ...................................................... 3Benefits of primary cells................................................................... 3Isolation of primary cells .................................................................. 3Primary cell culture .......................................................................... 3ATCC Primary Cell Solutions .......................................................... 5

ATCC Primary Human Endothelial Cell Solutions 6Introduction ...................................................................................... 6Cell Culture Protocols ...................................................................... 6

ATCC Primary Human Smooth Muscle Cell Solutions ....................................................................9

Introduction ...................................................................................... 9Cell Culture Protocols ...................................................................... 9

ATCC Primary Human Epithelial Cell Solutions . 12Introduction ....................................................................................12Cell Culture Protocols ....................................................................12

ATCC Primary Human Fibroblast Solutions ........ 15Introduction ....................................................................................15Cell Culture Protocols ....................................................................15

ATCC Primary Human Keratinocyte Solutions ... 18Introduction ....................................................................................18Cell Culture Protocols ....................................................................18

ATCC Primary Human Melanocyte Solutions ..... 21Introduction ....................................................................................21Cell Culture Protocols ....................................................................21

ATCC Human Mesenchymal Stem Cell and Differentiation Solutions .......................................24

Introduction ....................................................................................24Cell Culture Protocols ....................................................................25Adipose-derived Mesenchymal Stem Cell Differentiation Protocols ..........................................................................................26

References ............................................................. 28

Page 3Order online at www.atcc.org, call 800.638.6597, 703.365.2700, or contact your local distributor.

ATCC® PRIMARY CELL SOLUTIONS® Guide to Culturing Human Primary Cells

P R I M A R Y C E L L S A N D C E L L T Y P E SPrimary cell cultures more closely mimic the physiological state of cells in vivo and generate more relevant data representing living systems. Primary cultures consist of cells that have been freshly derived from a living organism and are maintained for growth in vitro. Primary cells can be categorized according to the genus from which they are isolated, as well as by species or tissue type. Each mamma-lian tissue type is derived from the embryonic germ layer consisting of ectoderm, endoderm and mesoderm, which differentiate into the many cell types that organize into tertiary structures such as skin, muscle, internal organs, bone and cartilage, the nervous system, blood and blood vessels.¹ The cell types most frequently found in primary cell culture are epithelial cells, fibroblasts, keratinocytes, melano-cytes, endothelial cells, muscle cells, hematopoietic and mesenchymal stem cells.

B A S I C P R O P E R T I E S O F P R I M A R Y C E L L SOnce adapted to in vitro culture conditions, primary cells undergo a limited, predetermined number of cell divisions before entering senescence. The number of times a primary cell culture can be passaged is minimal due to the Hayflick Limit, nutrient requirements and culture conditions, and the expertise by which they are manipulated and subcultured. In contrast, cell lines that have been immortalized by viral, hTERT, or tumorigenic transformation typically undergo unlimited cell division and have an infinite lifespan. And, unlike tumor cell lines cultured in medium containing 10% to 20% serum, primary cell cultures are fastidious, requiring optimized growth conditions, including the addition of tissue specific cytokines and growth factors for propagation in serum-free or low-serum growth media.

B E N E F I T S O F P R I M A R Y C E L L SPrimary cell cultures are commonly used as in vitro tools for pre-clinical and investigative biological research, such as studies of inter- and intracellular communication, developmental biology, and elucidation of disease mechanisms, such as cancer, Parkinson’s disease, and diabetes. Historically, investigators have employed immortalized cell lines in research related to tissue function; however, the use of cell lines containing gross mutations and chromosomal abnormalities provides poor indicators of normal cell phenotype and progression of early-stage disease. The use of primary cells, maintained for only short periods of time in vitro, now serves as the best representative of the main functional component of the tissue (in vivo) from which they are derived.

I S O L A T I O N O F P R I M A R Y C E L L SThe isolation and purification of peripheral blood cells can be easily achieved by differential centrifugation or by positive sorting using magnetic beads. On the other hand, the isolation of a pure population of cells from primary tissue is often difficult to perform, and requires knowledge of how the cell strata should be teased apart into a suspension containing only one predominant cell type. Diagram 1 is an illustration of some of the basic steps used to establish a primary cell culture.¹⁴

P R I M A R Y C E L L C U LT U R EGROWTH REQUIREMENTS

Primary cells, except for those derived from peripheral blood, are anchorage-dependent, adherent cells, meaning they require a surface in order to grow properly in vitro. In most cases, primary cells are cultured in a flat un-coated plastic vessel, but sometimes a microcar-rier, which can greatly increase the surface area, can be used. A complete cell culture media, composed of a basal medium supplemented with appropriate growth factors and cytokines, is required. During establishment of primary cultures, it may be useful to include an anti-biotic in the growth medium to inhibit contamination introduced from the host tissue. These may include a mixture of gentamicin, penicillin, streptomycin, and amphotericin B. However, long-term use of antibiotics is not advised, since some reagents, such as amphotericin B, may be toxic to cells over time.

MAINTENANCE

The maintenance phase begins when cells have attached to the surface of the culture dish. Attachment usually occurs about 24 hours after initiation of the culture. When initiating a culture of cryopreserved primary cells, it is important to remove the spent media once the cells have attached because DMSO is harmful to primary cells and may cause a drop in post-thaw viability. When cells have reached a desired percent of cellular confluence and are actively proliferating, it is time to subculture. It is best to subculture primary cell cultures before reaching 100% confluence, since post-confluent cells may undergo differentiation and exhibit slower proliferation after passaging.


Diagram 1: Basic steps used to isolate cells from primary tissue

TISSUE ACQUISITION

DISSECTION DISAGGREGATION INCUBATION & GROWTHSEPARATION & PURIFICATION

� Process primary tissue, removing fatty and necrotic cells

� Mechanical or enzymatic disaggregation

� Enzymes used:

▫ Trypsin

▫ Collagenase II

▫ Elastase

▫ Hyaluronidase

▫ DNase

� Incubate dispersed cells

� Change medium 24 hours after initiation to remove loose debris & unattached cells

Further purification of primary cells achieved by:

� Selective media

� Remove cells at different levels of attachment

� Immunomagnetic beads

CELLULAR CONFLUENCE

Cellular confluence refers to the percentage of the culture vessel inhabited by attached cells. For example, 100% cellular confluence means the surface area is completely covered by cells, while 50% confluence means roughly half of the surface is covered. It is an import-ant parameter to track and assess in primary cell culture because different cell types require different confluence end points, at which point they need to be subcultured.

Levels of cellular confluence

Human smooth muscle cells between 20% and 30% confluence

Human melanocyte cells between 50% and 60% confluence

Human keratinocytes at nearly 100% conflu-ence (note the formation of vacuoles and differentiated cells)

SUBCULTURE

Anchorage-dependent cells grow in monolayers and need to be subcultured at regular intervals to maintain exponential growth. Subculturing procedures, including recommended split-ratios and medium replenishment (feeding) schedules for each ATCC primary cell culture, are provided on the product information sheet provided with each cell (available online at www.atcc.org). Subcultivation of mono-layers involves the breakage of both inter- and intracellular cell-to-surface bonds. Most adherent primary cells require the digestion of their protein attachment bonds with a low concentration of a proteolytic enzyme such as trypsin/EDTA. After the cells have been disso-ciated and dispersed into a single-cell suspension, they are counted and diluted to the appropriate concentration and transferred to fresh culture vessels where they will reattach and divide.

CELL COUNTING

Hemocytometers are commonly used to estimate cell number and determine cell viability with the aid of an exclusion dye such as Trypan Blue or Erythrosin B. A hemocytometer is a fairly thick glass slide with 2 counting chambers, one on each side. Each counting chamber has a mirrored surface with a 3 × 3 mm grid consisting of 9 counting squares. The chambers have raised sides that will hold a coverslip exactly 0.1 mm above the chamber floor. Each of the 9 counting squares holds a volume of 0.0001 mL. Alternatively, counting cells can also be achieved by using an automated cell counter, such as Vi-CELL®.

For a detailed description of cell counting using a hemocytometer, refer to the ATCC Animal Cell Culture Guide: – available online at www.atcc.org.

https://www.atcc.org

https://www.atcc.org


CRYOPRESERVATION AND RECOVERY

Special attention is needed to cryopreserve and thaw primary cells in order to minimize cell damage and death during each process. Cryopreservation of human cells is best achieved with the use of a cryoprotectant, such as DMSO or glycerol. Most primary cell cultures can be cryopreserved in a mixture of 80% complete growth medium supplemented with 10% FBS and 10% DMSO. The freezing process should be slow, at a rate of -1°C per minute, to minimize the formation of ice crystals within the cells. Once frozen, cultures are stored in the vapor phase of liquid nitrogen, or below -130°C. Additional information about freezing cells can be found in ATCC Technical Document: Cryogenic Storage of Animal Cells, available online at www.atcc.org.

Thawing cryopreserved cells is a rapid process and is accomplished by immersing frozen cells in a 37°C water bath for about 1 to 2 minutes. Care should be taken not to centrifuge primary cells upon thaw, since they are extremely sensitive to damage during recovery from cryo-preservation. It is best to plate cells directly upon thaw, and allow cultures to attach for the first 24 hours before changing the medium to remove residual DMSO.

CHALLENGES OF PRIMARY CELL ISOLATION AND CULTURE

There are several challenges associated with the use of primary cells. One of the greatest hurdles primary cell culturists face is limited cell accessibility due to issues with donor tissue supply, difficulty with cell isolation/purification, quality assurance and consistency, and contamination risks. Data comparability is also a serious issue with primary cell use, and arises out of variability among reagents used and the procedures implemented by individual scientists and laboratories to isolate and culture primary cells. A comparison between primary cells and continuous cell lines is described in Table 1.

Table 1: Comparison between primary cells and continuous cell lines

Properties Primary cells Continuous cell lines

Life span & cell proliferation Finite; limited to a small number of cell doublings Infinite when handled properly

Consistency Variability exists between donors and preparations Minimal variability

Genetic integrity Retains in vivo tissue genetic makeup through cell doublings Subject to genetic drift as cells divide

Biological relevance More closely mimics the physiology of cells in vivo Relevance can drift over time as cells divide

Ease of use (freeze-thaw & use) Requires optimized culture conditions and careful handling Well established conditions and robust protocols exist

Time & expense to use More time and less abundance of cells Less time and more abundance of cells

A T C C P R I M A R Y C E L L S O L U T I O N SATCC has provided a solution to help investigators overcome the high cost and inconsistency found in routine primary cell culture with the development of ATCC Primary Cell Solutions, a standardized cell culture system that includes high quality cells, media, supplements, reagents, and protocols. ATCC Primary Cell Solutions focuses on providing researchers with superior quality from a trusted source – each lot of ATCC Primary Cell Solutions primary cells is:

CRYOPRESERVED AT EARLY PASSAGE � ATCC Primary Cell Solutions primary cells are frozen at passages 1 through 3

� Early passage material ensures higher viability and optimal plating efficiency

PERFORMANCE TESTED � ATCC Primary Cell Solutions cells, media, kit supplements, and reagents are tested for optimal reliability

� Growth and morphology are assessed to ensure all components work synergistically

QUALIT Y CONTROLLED TO ENSURE SAFET Y, PURIT Y, AND FUNCTIONALIT Y � Sterility testing - all cells are tested for bacteria, yeast, fungi, and Mycoplasma

� Viral testing - HIV-1, HIV-2, HBV, and HCV tissue screening is performed at isolation

� Viability and growth - viability and growth of each lot of cells is checked before freezing and after-thawing

� Staining - staining for cell-specific marker expression is determined and performed for some cell types

ATCC Primary Cell Solutions basal media and cell-specific growth kits are designed to support recovery and proliferation of ATCC Primary Cell Solutions primary cells in vitro. Used as a system, ATCC Primary Cell Solutions primary cells, basal media, and cell-specific growth kits provide all the components needed to be successful in primary cell research. (Detailed formulations for each growth kit can be found at www.atcc.org.)

http://www.atcc.org


ATCC PRIMARY HUMAN ENDOTHELIAL CELL SOLUTIONSI N T R O D U C T I O NEndothelial cells form the endothelium - the thin layer of cells that line the interior surface of blood vessels forming a smooth anticoagulant surface that functions as a selective filter to regulate the passage of gases, fluid, immune cells, and various molecules.¹⁴ Human endothelial cells can be isolated from human umbilical vein, the aorta, the pulmonary and coronary arteries, and the skin, and serve as useful tools in the study of angiogenesis, cancer therapy, wound healing, burn therapy, high-throughput and high-con-tent screening projects, cell signaling studies, gene expression profiling, toxicology screening, tissue engineering, and regeneration.

ATCC Primary Human Endothelial Cells can be cultured in complete growth medium containing either bovine brain extract (BBE) or vascular endothelial growth factor (VEGF). Use of the Endothelial Cell Growth Kit-VEGF (ATCC® PCS-100-041) will support a faster rate of proliferation, while the Endothelial Cell Growth Kit-BBE (ATCC PCS-100-040) is recommended if a less defined cell culture medium is desired.

C E L L C U LT U R E P R O T O C O L SMATERIALS NEEDED

Table 2: Primary cells and complete growth medium

Endothelial Cells Growth Kit Options* Basal Medium

Umbilical Vein Endothelial Cells, Normal, Human (ATCC PCS-100-010)Choose ONE:

Endothelial Cell Growth Kit-BBE (ATCC PCS-100-040)

Endothelial Cell Growth Kit-VEGF (ATCC PCS-100-041)

Vascular Cell Basal Medium (ATCC PCS-100-030)

Umbilical Vein Endothelial Cells, Normal, Human, Pooled (ATCC PCS-100-013)

Aortic Endothelial Cells; Normal, Human (ATCC PCS-100-011)

Coronary Artery Endothelial Cells, Normal, Human (ATCC PCS-100-020),

Pulmonary Artery Endothelial Cells, Normal, Human (ATCC PCS-100-022),

Dermal Microvascular Endothelial Cells, Normal, Human, Neonatal (ATCC PCS-110-010)

Choose ONE:

Microvascular Endothelial Cell Growth Kit-BBE (ATCC PCS-110-040)

Microvascular Endothelial Cell Growth Kit-VEGF (ATCC PCS-110-041)

Reagents for Subculture

D-PBS (ATCC 30-2200)

Trypsin-EDTA for Primary Cells (ATCC PCS-999-003)

Trypsin Neutralizing Solution (ATCC PCS-999-004)

*Phenol red and antibiotics may be added if desired, and are listed in the appendix.

PREPARATION OF COMPLETE GROWTH MEDIA1 Obtain 1 growth kit from the freezer; make sure that the caps of all components are tight.

2 Thaw the components of the growth kit just prior to adding them to the basal medium. It is necessary to warm the L-glutamine component in a 37°C water bath and shake to dissolve any precipitates prior to adding to the basal medium.

3 Obtain 1 bottle of Vascular Cell Basal Medium from cold storage.

4 Decontaminate the external surfaces of all growth kit component vials and the basal medium bottle by spraying them with 70% ethanol.

5 Using aseptic technique, and working in a laminar flow hood or biosafety cabinet, transfer the volume of each growth kit compo-nent (volumes for each growth kit are provided on the product information sheet; the following table (Table 3) represents the Endothelial Cell Growth Kit-VEGF) to the bottle of basal medium using a separate sterile pipette for each transfer.

6 Tightly cap the bottle of complete growth medium and swirl the contents gently to assure a homogeneous solution. Do not shake forcefully to avoid foaming. Label and date the bottle.

7 Complete growth media should be stored in the dark at 2°C to 8°C (do not freeze). When stored under these conditions, complete growth media is stable for 30 days.

Primary Dermal Micovascular Endothelial Cells, Normal, Human, Neonatal (ATCC PCS-110-010)

https://www.atcc.org/products/pcs-100-041



https://www.atcc.org/products/PCS-100-010











https://www.atcc.org/products/30-2200





Table 3: Endothelial Cell Growth Kit-VEGF (ATCC PCS-100-041)

Component Volume Final Concentration

rh VEGF 0.5 mL 5 ng/mL

rh EGF 0.5 mL 5 ng/mL

rh FGF basic 0.5 mL 5 ng/mL

rh IGF-1 0.5 mL 15 ng/mL

L-glutamine 25.0 mL 10 mM

Heparin sulfate 0.5 mL 0.75 Units/mL

Hydrocortisone hemisuccinate 0.5 mL 1 µg/mL

Fetal Bovine Serum 10.0 mL 2%

Ascorbic acid 0.5 mL 50 µg/mL

HANDLING PROCEDURE FOR FROZEN CELLS AND INITIATION OF CULTURES1 Refer to the batch specific information provided on the last page of the product information sheet for the total number of viable

cells recovered from each lot of ATCC Primary Human Endothelial Cells.

2 Using the total number of viable cells, determine how much surface area can be inoculated to achieve an initial seeding density between 2,500 and 5,000 cells per cm² for most Primary Human Endothelial Cells offered by ATCC; the exception being Primary Dermal Microvascular Endothelial Cells, which should be seeded at a density of 5,000 cells per cm².

3 Prepare the desired combination of flasks. Add 5 mL of complete growth media per 25 cm² of surface area. Place the flasks in a 37°C, 5% CO₂, humidified incubator and allow the media to pre-equilibrate to temperature and pH for 30 minutes prior to adding cells.

4 While the culture flasks equilibrate, remove 1 vial of ATCC Primary Human Endothelial Cells from storage and thaw the cells by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 1 to 2 minutes).

5 Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All operations from this point onward should be carried out under strict aseptic conditions.

6 Add the appropriate volume of complete growth media [volume = (1 mL x number of flasks to be seeded) – 1 mL] into a sterile conical tube. Using a sterile pipette, transfer the cells from the cryovial to the conical tube. Gently pipette the cells to homogenize the suspension. Do not centrifuge.

7 Transfer 1.0 mL of the cell suspension to each of the pre-equilibrated culture flasks prepared in steps 1 to 3 of Handling Procedure for Frozen Cells and Initiation of Cultures. Pipette several times, then cap and gently rock each flask to evenly distribute the cells.

8 Place the seeded culture flasks in the incubator at 37°C with a 5% CO₂ atmosphere. Incubate for at least 24 hours before processing the cells further.

MAINTENANCE 1 Before beginning, pre-warm complete growth media in a 37°C water bath. This will take between 10 and 30 minutes, depending on

the volume. If using a small volume of medium (50 mL or less), warm only the volume needed in a sterile conical tube. Avoid warming complete growth media multiple times.

2 24 hours after seeding, remove the cells from the incubator and view each flask under the microscope to determine percent cellular confluence.

3 Carefully remove the spent media without disturbing the monolayer.

4 Add 5 mL of fresh, pre-warmed complete growth media per 25 cm² of surface area and return the flasks to the incubator.

5 After 24 to 48 hours, view each flask under the microscope to determine percent cellular confluence. If not ready to passage, repeat steps 3 and 4 as described above. When cultures have reached approximately 80% confluence, and are actively proliferating (many mitotic figures are visible), it is time to subculture. Subculture endothelial cells before reaching confluence; post-confluent primary endothelial cells may exhibit slower proliferation after passaging.

SUBCULTURE1 Passage Primary Human Endothelial Cells when cultures have reached approximately 80% confluence.

2 Warm both the Trypsin-EDTA for Primary Cells (ATCC PCS-999-003) and the Trypsin Neutralizing Solution (ATCC PCS-999-004) to room temperature prior to dissociation. Warm complete growth medium to 37°C prior to use with the cells.

3 For each flask, carefully aspirate the spent media without disturbing the monolayer.

4 Rinse the cell layer two times with 3 to 5 mL D-PBS (ATCC 30-2200) to remove residual traces of serum.






5 Add pre-warmed trypsin-EDTA solution (1 to 2 mL for every 25 cm²) to each flask.

6 Gently rock each flask to ensure complete coverage of the trypsin-EDTA solution over the cells, and then aspirate the excess fluid off of the monolayer.

7 Observe the cells under the microscope. When the cells pull away from each other and round up (typically within 3 to 5 minutes), remove the flask from the microscope and gently tap it from several sides to promote detachment of the cells from the flask surface.

8 When the majority of cells appear to have detached, quickly add an equal volume of Trypsin Neutralizing Solution (ATCC PCS-999-004) to each flask. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized.

9 Transfer the dissociated cells to a sterile centrifuge tube and set aside while processing any remaining cells in the flask.

10 Add 3 to 5 mL D-PBS (ATCC 30-2200) to the flask to collect any additional cells that might have been left behind.

11 Transfer the cell/D-PBS suspension to the centrifuge tube containing the trypsin-EDTA-dissociated cells.

12 Repeat steps 10 and 11 as needed until all cells have been collected from the flask.

13 Centrifuge the cells at 150 x g for 3 to 5 minutes.

14 Aspirate the neutralized dissociation solution from the cell pellet and resuspend the cells in 2 to 8 mL fresh, pre-warmed, complete growth medium.

15 Count the cells and seed new flasks at a density of 2,500 to 5,000 cells per cm²; however, be sure to seed Primary Dermal Microvascular Endothelial Cells at 5,000 cells per cm².

16 Place newly seeded flasks in a 37°C, 5% CO₂, incubator for at least 24 to 48 hours before processing the cells further. Refer to Maintenance for guidelines on feeding.





ATCC PRIMARY HUMAN SMOOTH MUSCLE CELL SOLUTIONSI N T R O D U C T I O N Vascular tissue is made up of a diverse population of cell types, including endothelial cells, smooth muscle cells, pericytes, fibroblasts, and other connective tissue cell types. Together these cell types form tight junctions or connections, which allow for permeability for both passive and active trans-port across the vessel wall. Vascular smooth muscle cells make up the smooth muscle layer of blood vessels and can be co-cultured with vascular endothelium.¹⁴ Smooth muscle cells isolated from human ascending (thoracic) and descending (abdominal) aorta, coronary artery, and pulmonary artery are useful for studying vascular diseases such as thrombosis and atherosclerosis.



Smooth Muscle Cells Growth Kit Options* Basal Medium

Aortic Smooth Muscle Cells, Normal, Human (ATCC PCS-100-012)

Vascular Smooth Muscle Cell Growth Kit (ATCC PCS-100-042)

Vascular Cell Basal Medium (ATCC PCS-100-030)

Coronary Artery Smooth Muscle Cells, Normal, Human (ATCC PCS-100-021)

Pulmonary Artery Smooth Muscle Cells, Normal, Human (ATCC PCS-100-023)

Lung Smooth Muscle Cells, Normal, Human (ATCC PCS-130-010)

Bronchial/Trachial Smooth Muscle Cells, Normal, Human (ATCC PCS-130-011)

Bladder Smooth Muscle Cells, Normal, Human (ATCC PCS-420-012)

Uterine Smooth Muscle Cells, Normal, Human (ATCC PCS-460-010)






PREPARATION OF COMPLETE GROWTH MEDIA 1 Obtain 1 growth kit from the freezer; make sure that the caps of all components are tight.


3 Obtain 1 bottle of Vascular Cell Basal Medium from cold storage.


5 Using aseptic technique, and working in a laminar flow hood or biosafety cabinet, transfer the volume of each growth kit component, as indicated in the following table to the bottle of basal medium using a separate sterile pipette for each transfer.

Table 5: Vascular Smooth Muscle Cell Growth Kit (ATCC PCS-100-042)


rh FGF-basic 0.5 mL 5 ng/mL

rh Insulin 0.5 mL 5 µg/mL


L-glutamine 25.0 mL 10 mM

rh EGF 0.5 mL 5 ng/mL


Primary Aortic Smooth Muscle Cells, Normal, Human (ATCC PCS-100-012)

ATCC Primary Cell Solutions aortic smooth muscle cells (ATCC PCS-100-012) dual stained for von Willebrand factor (green) as a marker for endothelial cells and smooth muscle α-actin (red) after differentiation.




















cells recovered from each lot of ATCC Primary Human Smooth Muscle Cells.

2 Using the total number of viable cells, determine how much surface area can be inoculated to achieve an initial seeding density between 2,500 and 5,000 cells per cm².

3 Prepare the desired combination of flasks. Add 5 mL of complete growth media per 25 cm² of surface area. Place the flasks in a 37°C, 5% CO₂, humidified incubator and allow the media to pre-equilibrate to temperature and pH for 30 minutes prior to adding cells.

4 While the culture flasks equilibrate, remove 1 vial of ATCC Primary Human Smooth Muscle Cells from storage and thaw the cells by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 1 to 2 minutes).




8 Place the seeded culture flasks in the incubator at 37°C with a 5% CO₂ atmosphere. Incubate for at least 24 hours before processing the cells further.



2 24 to 36 hours after seeding, remove the cells from the incubator and view each flask under the microscope to determine percent cellular confluence.



5 After 24 to 48 hours, view each flask under the microscope to determine percent cellular confluence. If not ready to passage, repeat steps 3 and 4 as described above. When cultures have reached approximately 80% to 90% confluence, and are actively proliferating (many mitotic figures are visible), it is time to subculture. Vascular smooth muscle cells are contact inhibited; post-confluent vascular smooth muscle cells may not proliferate after passaging.

SUBCULTURE1 Passage normal vascular smooth muscle cells when the culture has reached approximately 80% confluence.

2 Warm both the Trypsin-EDTA for Primary Cells (ATCC PCS-999-003) and the Trypsin Neutralizing Solution (ATCC PCS-999-004) to room temperature prior to dissociation. Warm complete growth medium to 37°C prior to use with the cells.


4 Rinse the cell layer two times with 3 to 5 mL D-PBS (ATCC 30-2200) to remove residual traces of serum.




8 When the majority of cells appear to have detached, quickly add an equal volume of Trypsin Neutralizing Solution (ATCC PCS-999-004) to each flask. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized.

NOTE:

Cells are typically ready to passage after 7 to 9 days in culture when inoculated with 2,500 cells/cm².







9 Transfer the dissociated cells to a sterile centrifuge tube and set aside while processing any remaining cells in the flask.

10 Add 3 to 5 mL D-PBS (ATCC 30-2200) to the flask to collect any additional cells that might have been left behind.





15 Count the cells and seed new flasks at a density of 2,500 to 5,000 cells per cm².

16 Place newly seeded flasks in a 37°C, 5% CO₂, incubator for at least 24 to 48 hours before processing the cells further. Refer to Maintenance for guidelines on feeding.



ATCC PRIMARY HUMAN EPITHELIAL CELL SOLUTIONSI N T R O D U C T I O N Epithelia are tissues found throughout the body. They line the cavities of glands and organs in the body and also cover flat surfaces, such as skin. Epithelial cells are polarized cells that discriminate between an apical and basolateral compartment. They perform a variety of functions depending on their loca-tion, including boundary and protection, sensory, secretion, transportation, absorption, and diffusion. One challenging aspect of culturing primary epithelial cells is overgrowth of stromal cells. Stromal fibroblasts can be inhibited by culturing explants in low serum or serum-free culture media, limiting the calcium concentration in the growth medium, selectively inhibiting fibroblasts with agents, or by targeting with antimesodermal antibodies.¹⁴ ATCC Primary Cell Solutions offers epithelial cells isolated from human bronchi, trachea, and small airways, as well as the cornea, prostate, and kidneys. The usefulness of such cultures has been found in studies related to inflam-mation, microbial infection, and pathogenesis including influenza, cancer, toxicology, gene regulation and tissue development, cell-matrix interactions, as well as application in toxicology testing and drug screening/development.



Epithelial Cells Growth Kit Options* Basal Medium

Small Airway Epithelial Cells; Normal, Human (ATCC PCS-301-010)

Small Airway Epithelial Cell Growth Kit (ATCC PCS-301-040)

Airway Epithelial Cell Basal Medium (ATCC PCS-300-030)

Bronchial/Tracheal Epithelial Cells; Normal, Human (ATCC PCS-300-010)

Bronchial Epithelial Cell Growth Kit (ATCC PCS-300-040)

Lobar Bronchial Epithelial Cells; Normal, Human (ATCC PCS-300-015)

Bronchial Epithelial Cell Growth Kit (ATCC PCS-300-040)

Renal Proximal Tubule Epithelial Cells; Normal, Human (ATCC PCS-400-010)

Renal Epithelial Cell Growth Kit (ATCC PCS-400-040)

Renal Epithelial Cell Basal Medium (ATCC PCS-400-030)

Renal Cortical Epithelial Cells; Normal, Human (ATCC PCS-400-011)

Renal Mixed Epithelial Cells; Normal, Human (ATCC PCS-400-012)

Bladder Epithelial Cells (A/T/N); Normal, Human (ATCC PCS-420-010)

Bladder Epithelial Growth Kit (ATCC PCS-420-042)

Bladder Epithelial Basal Medium (ATCC PCS-420-032)

Prostate Epithelial Cells; Normal, Human (ATCC PCS-440-010) Prostate Epithelial Cell Growth Kit (ATCC PCS-440-040)

Prostate Epithelial Cell Basal Medium (ATCC PCS-440-030)

Vaginal Epithelial Cells; Normal, Human (ATCC PCS-480-010) Vaginal Epithelial Growth Kit (ATCC PCS-480-040)

Vaginal Epithelial Basal Medium (ATCC PCS-480-030)

Cervical Epithelial Cells; Normal, Human (ATCC PCS-480-011) Cervical Epithelial Cell Growth Kit (ATCC PCS-480-042)

Cervical Epithelial Cell Basal Medium (ATCC PCS-480-032)

Mammary Epithelial Cells; Normal, Human (ATCC PCS-600-010)

Mammary Epithelial Cell Growth Kit (ATCC PCS-600-040)

Mammary Epithelial Cell Basal Medium (ATCC PCS-600-030)

Corneal Epithelial Cells; Normal, Human (ATCC PCS-700-010) Corneal Epithelial Cell Growth Kit (ATCC PCS-700-040)

Corneal Epithelial Cell Basal Medium (ATCC PCS-700-030)






PREPARATION OF COMPLETE GROWTH MEDIA1 Obtain 1 Epithelial Cell Growth Kit (corresponding to the epithelial cell type being used) from the freezer; make sure that the caps

of all components are tight.

2 Thaw the components of the growth kit just prior to adding them to the basal medium.

3 Obtain 1 bottle of Epithelial Cell Basal Medium (corresponding to the epithelial cell being used) from cold storage.


Primary Prostate Epithelial Cells; Normal, Human (ATCC PCS-440-010)




































5 Using aseptic technique and working in a laminar flow hood or biosafety cabinet, transfer the indicated volume of each growth kit component as indicated in the culture’s corresponding product information sheet, to the bottle of basal medium using a separate sterile pipette for each transfer.




cells recovered from each lot of ATCC Primary Human Epithelial Cells.

2 Using the total number of viable cells, determine how much surface area can be inoculated to achieve an initial seeding density of 5,000 cells per cm².

3 Prepare the desired combination of flasks. Add 5 mL of complete growth medium per 25 cm² of surface area. Place the flasks in a 37°C, 5% CO₂, humidified incubator and allow the media to pre-equilibrate to temperature and pH for 30 minutes prior to adding cells.

4 While the culture flasks equilibrate, remove 1 vial of ATCC Primary Human Epithelial Cells from storage and thaw the cells by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 1 to 2 minutes).


6 Add the appropriate volume of complete growth medium [volume = (1 mL x number of flasks to be seeded) – 1 mL] into a sterile conical tube. Using a sterile pipette, transfer the cells from the cryovial to the conical tube. Gently pipette the cells to homogenize the suspension. Do not centrifuge.


8 Place the seeded culture flasks in the incubator at 37°C, 5% CO₂ atmosphere. Incubate for at least 24 hours before processing the cells further.





4 Add 5 mL of fresh, pre-warmed complete growth medium per 25 cm² of surface area and return the flasks to the incubator.

5 After 24 to 48 hours, view each flask under the microscope to determine percent cellular confluence. If not ready to passage, repeat steps 3 and 4 as described above. When cultures have reached about 80% confluence, and are actively proliferating (many mitotic figures are visible), it is time to subculture.

SUBCULTURE1 Passage normal human epithelial cells when the culture has reached about 80% confluence.

2 Warm both the Trypsin-EDTA for Primary Cells (ATCC PCS-999-003) and the Trypsin Neutralizing Solution (ATCC PCS-999-004) to room temperature prior to dissociation. Warm the complete growth medium to 37°C prior to use with the cells.


4 Rinse the cell layer one time with 3 to 5 mL D-PBS (ATCC 30-2200) to remove residual medium.




8 When the majority of cells appear to have detached, quickly add an equal volume of the Trypsin Neutralizing Solution (ATCC PCS-999-004) to each flask. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized.






9 Transfer the dissociated cells to a sterile centrifuge tube and set aside while processing any remaining cells in the culture flask.

10 Add 3 to 5 mL D-PBS (ATCC 30-2200) to the tissue culture flask to collect any additional cells that might have been left behind.




14 Aspirate neutralized dissociation solution from the cell pellet and resuspend the cells in 2 to 8 mL fresh, pre-warmed, complete growth medium.

15 Count the cells and seed new culture flasks at a density of 5,000 viable cells per cm².

16 Place newly seeded flasks in a 37°C, 5% CO₂ incubator for at least 24 to 48 hours before processing the cells further. Refer to Maintenance for guidelines on feeding.



ATCC PRIMARY HUMAN FIBROBLAST SOLUTIONSI N T R O D U C T I O N Fibroblasts play an important role in maintaining the structural integrity of connective tissue, and synthesize extracellular matrix proteins such as collagens, glycosaminoglycans, and glycoproteins.¹⁵,¹⁶ Fibroblasts are morphologically heterogeneous, and their appearance is dependent on in vivo location and activity. Injury of tissue displays a proliferative stimulus for fibroblasts and induces them to produce wound healing proteins. Fibroblasts used in primary cell culture are commonly isolated from the dermis layer of human neonatal foreskin or adult skin. They are frequently used in studies related to wound healing, tissue engineering and regeneration applications, and the induction of pluripotent stem (iPS) cells. Fibroblasts, treated with mitomycin C to inhibit proliferation, have been extensively used as feeder layers to enhance the cultivation of human stem cells and keratinocytes in vitro.

ATCC Primary Human Fibroblasts can be cultured in complete growth medium with or without serum. The use of Fibroblast Growth Kit–Serum-free creates a completely defined medium for the serum-free culture of human fibroblasts. The rate of proliferation is equal to or greater than media supplemented using FBS (at concentrations ranging from 2% to 10%) through 10 population doublings.



Fibroblasts Growth Kit Options* Basal Medium

Dermal Fiboblasts; Normal, Human Neonatal (ATCC PCS-201-010)

Choose ONE:

Fibroblast Growth Kit – Serum-free (ATCC PCS-201-040)

Fibroblast Growth Kit – Low Serum (ATCC PCS-201-041)

Fibroblast Basal Medium (ATCC PCS-201-030)

Dermal Fiboblasts; Normal, Human, Adult (ATCC PCS-201-012)

Lung Fibroblasts; Normal, Human (ATCC PCS-201-013)

Gingival Fibroblasts; Normal, Human (ATCC PCS-201-018)

Bladder Fibroblasts; Normal, Human (ATCC PCS-420-013)

Uterine Fibroblast, Normal, Human (ATCC PCS-460-010)






PREPARATION OF COMPLETE GROWTH MEDIA1 Obtain 1 growth kit from the freezer; make sure that the caps of all containers are tight.

2 Thaw the components of the growth kit just prior to adding them to the basal medium. It is necessary to warm the L-glutamine component in a 37°C water bath, and shake to dissolve any precipitates prior to adding to the basal medium.

3 Obtain one bottle of Fibroblast Basal Medium from cold storage.


5 Using aseptic technique and working in a laminar flow hood or biosafety cabinet, transfer the volume of each growth kit compo-nent, as indicated in the following tables, to the bottle of basal medium using a separate sterile pipette for each transfer.

Primary adult human dermal fibroblasts (ATCC PCS-201-012) cultured in serum-free medium.















Table 8: Fibroblast Growth Kit–Serum-free (ATCC PCS-201-040)


L-glutamine 18.75 mL 7.5 mM

Hydrocortisone Hemisuccinate 0.5 mL 1 µg/mL

HLL Supplement 1.25 mL

HSA 500 µg/mL

Linoleic Acid 0.6 µM

Lecithin 0.6 µg/mL

rh FGF β 0.5 mL 5 ng/mL

rh EGF / TGF β-1 Supplement 0.5 mL5 ng/mL

30 pg/mL



Table 9: Fibroblast Growth Kit–Low Serum (ATCC PCS-201-041)


rh FGF β 0.5 mL 5 ng/mL

L-glutamine 18.75 mL 7.5 mM


Hydrocortisone Hemisuccinate 0.5 mL 1 µg/mL





HANDLING PROCEDURE FOR FROZEN CELLS AND INITIATION OF CULTURES1 Refer to the batch specific information provided on the last page of the product

information sheet for the total number of viable cells recovered from each lot of ATCC Primary Human Fibroblasts.

2 Using the total number of viable cells reported, determine how much surface area can be inoculated to achieve an initial seeding density of 2,500 to 5,000 cells per cm² for untreated fibroblasts. Note: Mitomycin C treated fibroblasts should be seeded at a density of 20,000 to 40,000 cells per cm² for use with stem cells.

3 Prepare the desired combination of flasks. Add 5mL of complete growth medium per 25 cm² of surface area. Place the flasks in a 37°C, 5% CO₂, humidified incubator and allow the media to pre-equilibrate to temperature and pH for 30 minutes prior to adding cells.

4 While the culture flasks equilibrate, remove 1 vial of corresponding ATCC Primary Human Fibroblasts from storage and thaw the cells by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 1 to 2 minutes).



7 Transfer 1 mL of the cell suspension to each of the pre-equilibrated culture flasks prepared in steps 1 to 3 of Handling Procedure for Frozen Cells and Initiation of Cultures. Pipette several times, then cap and gently rock each flask to evenly distribute the cells.

8 Place the seeded culture flasks in the incubator at 37°C, 5% CO₂ atmosphere. Incubate at least 24 hours before processing the cells further.

NOTE:

Gelatin-Coated Tissue Culture Flasks are needed to culture Mitomycin C Treated Dermal Fibroblasts (ATCC PCS-201-011) in order to achieve optimal cell attach-ment. Culture flasks should be prepared before thawing cells. Non-coated tissue culture flasks can also be used, if needed.










5 After 24 to 48 hours, view each flask under the microscope to determine percent cellular confluence. If not ready to passage, repeat steps 3 and 4 as described above. When cultures have reached 80% to 100% confluence, and are actively proliferating (many mitotic figures are visible), it is time to subculture. Fibroblasts are not a contact inhibited cell type.

SUBCULTURE 1 Passage normal human fibroblasts when the cells have reached approximately 80% to

100% confluence and are actively proliferating.



4 Rinse the cell layer two times with 3 to 5 mL of D-PBS per 25 cm² of surface area (ATCC 30-2200) to remove any residual traces of serum. Rinse the cell layer one time with 3 to 5 mL of D-PBS if serum-free culture conditions are used.



7 Observe the cells under the microscope. When the cells pull away from each other and round up (typically within about 3 to 5 minutes), remove the flask from the microscope and gently tap it from several sides to promote detachment of the cells from the flask surface.

8 When the majority of cells appear to have detached, quickly add to each flask, a volume of the Trypsin Neutralizing Solution (ATCC PCS-999-004) equal to the volume of trypsin-EDTA solution used previously. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized.







15 Count the cells and seed new culture flasks at a density of 2,500 to 5,000 cells per cm².


NOTE:

Mitomycin C treated fibroblasts are mitot-ically arrested and cannot be subcultured.







ATCC PRIMARY HUMAN KERATINOCYTE SOLUTIONSI N T R O D U C T I O N Keratinocytes are the most common type of skin cells making up the majority of the epidermis. Dividing keratinocytes produce keratin (a protein that provides strength to skin, hair, and nails) and migrate to the surface of the skin, the stratum corneum, where they serve as the most abundant cells in the skin’s outermost layer.¹⁷ Once present in the stratum corneum, keratinocytes differentiate, stop dividing as cornified cells¹⁸ and eventually undergo apoptosis. Keratinocytes can be isolated from different loca-tions of the body. However, the most utilized keratinocytes in primary cell culture have been isolated from the epidermis of human juvenile foreskin or human adult skin, the latter of which is significant in the study of adult diseases such as psoriasis and skin cancer.¹⁴ Keratinocytes cultured in serum-free, low calcium growth medium will maintain the cells in an un-differentiated, proliferative state while inhibiting fibroblast outgrowth. Keratinocytes are useful for a number of scientific applications including the study of growth factor behavior, wound healing, toxicity/irritancy studies, and use as target cells for derivation of induced pluripotent stem cells.



Keratinocytes Growth Kit Options* Basal Medium

Epidermal Keratinocyte; Normal, Human, Neonatal Foreskin (ATCC PCS-200-010) Keratinocyte Growth Kit (ATCC PCS-200-040)

Dermal Cell Basal Medium (ATCC PCS-200-030)Epidermal Keratinocyte; Normal, Human, Adult (ATCC PCS-200-011)

Gingival Keratinocyte; Normal, Human (ATCC PCS-200-014)






PREPARATION OF COMPLETE GROWTH MEDIA1 Obtain 1 Keratinocyte Growth Kit from the freezer; make sure that the caps of all components are tight.


3 Obtain 1 bottle of Dermal Cell Basal Medium from cold storage.


5 Using aseptic technique and working in a laminar flow hood or biosafety cabinet, transfer the indicated volume of each growth kit component, as indicated in the following table, to the bottle of basal medium using a separate sterile pipette for each transfer.

Table 11: Keratinocyte Growth Kit (ATCC PCS-200-040)


Bovine Pituitary Extract (BPE) 2.0 mL 0.4%

rh TGF-α 0.5 mL 0.5 ng/mL

L-Glutamine 15.0 mL 6 mM

Hydrocortisone Hemisuccinate 0.5 mL 100 ng/mL

rh Insulin 0.5 mL 5 µg/ml

Epinephrine 0.5 mL 1.0 µM

Apo-Transferrin 0.5 mL 5 µg/ml



Primary Epidermal Keratinocytes; Normal, Human, Adult (ATCC PCS-200-011)













cells recovered from each lot of ATCC Primary Human Keratinocytes.

2 Using the total number of viable cells, determine how much surface area can be inoculated to achieve an initial seeding density between 2,500 and 5,000 cells per cm².


4 While the culture flasks equilibrate, remove 1 vial of ATCC Primary Human Keratinocytes from storage and thaw the cells by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 1 to 2 minutes).



7 Transfer 1.0 ml of the cell suspension to each of the pre-equilibrated culture flasks prepared in steps 1 to 3 of Handling Procedure for Frozen Cells and Initiation of Cultures. Pipette several times, then cap and gently rock each flask to evenly distribute the cells.







5 After 24 to 48 hours, view each flask under the microscope to determine percent cellular confluence. If not ready to passage, repeat steps 3 and 4 as described above. When cultures have reached approximately 80% confluence, and are actively proliferating (many mitotic figures are visible), it is time to subculture. Keratinocytes will begin to terminally differentiate once they become 100% confluent.

SUBCULTURE1 Passage normal keratinocytes when the culture has reached approximately 70% to 80% confluence.













NOTE:

If cells are difficult to detach, incubate each flask containing cells and the trypsin-EDTA solution at 37°C to facilitate dispersal.











ATCC PRIMARY HUMAN MELANOCYTE SOLUTIONSI N T R O D U C T I O N Melanocytes are found mainly in the epidermis, but may occur elsewhere in the body such as in the matrix of the hair. They are specialized skin cells that produce the pigment melanin, which gives skin its color and protects it from the hazardous effects of UV radiation. The most useful melanocytes for research are isolated from the epidermis of human juvenile foreskin or human adult skin. Special care must be taken to prevent contamination of melanocyte cultures with keratinocytes or fibroblasts found in the epidermis. Lowering the concentration of calcium in the medium to 60 µM and selecting for adherent melanocytes in hormone-supplemented medium aids in the isolation of melanocytes from epidermal tissue.¹⁴ Melanocytes are frequently used in the in vitro study of wound healing, and as testing models for toxicity/irritancy studies, melanoma, dermal response to UV radiation, psoria-sis and other skin diseases, and cosmetic research (eg, skin lightening compounds, skin protecting compounds).



Melanocytes Growth Kit Options Basal Medium

Epidermal Melanocytes; Normal, Human, Neonatal (ATCC PCS-200-012) Melanocyte Growth Kit (ATCC PCS-200-041) Dermal Cell Basal Medium (ATCC

PCS-200-030)Epidermal Melanocytes; Normal, Human, Adult (ATCC PCS-200-013) Adult Melanocyte Growth Kit (ATCC

PCS-200-042)






PREPARATION OF COMPLETE GROWTH MEDIA1 Obtain 1 Melanocyte Growth Kit (corresponding to the melanocyte being used) from the freezer; make sure that the caps of all

components are tight.


3 Obtain 1 bottle of Dermal Cell Basal Medium from cold storage.



Table 13: Melanocyte Growth Kit (ATCC PCS-200-041)


rh Insulin 0.5 mL 5 µg/ml

Ascorbic Acid 0.5 mL 50 µg/ml

L-Glutamine 15.0 mL 6 mM

Epinephrine 0.5 mL 1.0 µM

Calcium Chloride 80 µl 0.2 mM

M8 Supplement 5 ml Proprietary formulation



Adult human melanocytes (ATCC PCS-200-013).













cells recovered from each lot of ATCC Primary Human Melanocytes.



4 While the culture flasks equilibrate, remove 1 vial of ATCC Primary Human Melanocytes from storage and thaw the cells by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 1 to 2 minutes).







2 24 to 36 hours after seeding, remove the cells from the incubator and view each flask under the microscope to determine percent cellular confluence.



5 After 24 to 48 hours, view each flask under the microscope to determine percent cellular confluence. If not ready to passage, repeat steps 3 and 4 as described above. When cultures have reached 80% to 90% confluence, and are actively proliferating (many mitotic figures are visible), it is time to subculture. Melanocytes are not contact inhibited; however, they will proliferate best if the cells are passaged prior to 100% confluence. Melanocytes from lightly pigmented tissue should reach 80% confluence in 7 to 9 days.

SUBCULTURE1 Passage normal melanocytes when the culture has reached approximately 80% to 90% confluence.



4 Rinse the cell layer two times with 3 to 5 mL D-PBS (ATCC 30-2200) to remove residual medium.









NOTE:

Melanocytes are sensitive to over-trypsinization.












ATCC HUMAN MESENCHYMAL STEM CELL AND DIFFERENTIATION SOLUTIONSI N T R O D U C T I O N ATCC Human Mesenchymal Stem Cells (MSCs) are self-renewing multipotent adult stem cells. MSCs are traditionally found in the bone marrow, but can also be isolated from other tissues including adipose, human umbilical cord or cord blood, and peripheral blood. Adipose-derived mesenchymal stem cells are isolated from human adipose (fat) tissues by lipoaspiration or biopsy. Umbilical cord derived mesen-chymal stem cells are isolated from Wharton’s Jelly found in human umbilical cord. Although MSCs from primary adipose tissue and Wharton’s Jelly are considered to be relatively easy to obtain, isolation of consistent stem cell populations from such material is costly and time-consuming. Lipoaspirates and umbilical cord tissue represent a heterogeneous mixture of cell types, including adipocytes, endo-thelial cells, smooth muscle, pericytes and progenitor cells.² The inherent heterogeneity of this source material, then, yields a high potential for cellular contamination to predominate cultures.

To ensure the purity of ATCC Primary Cell Solutions Normal Human Mesenchymal Stem Cells, each batch is isolated from single-donor tissue, cryopreserved in the second passage, and tested for:

1 Authentication of growth and morphology, including adherence to plastic when cultured in optimized growth medium consisting of Mesenchymal Stem Cell Basal Medium (ATCC PCS-500-030) supplemented with Mesenchymal Stem Cell Growth Kit-Low Serum (ATCC PCS-500-040)

2 Verification of surface antigen expression,¹³ including a total of 10 markers: Positive (≥ 95%) for CD29, CD44, CD73, CD90, CD105, and CD166; and, negative (≥ 2%) for CD14, CD31, CD34, and CD45

3 Confirmation of multi-lineage differentiation into osteoblasts, adipocytes, and chondrocytes using optimized differentiation kits and protocols

MSCs are useful tools for non-controversial stem cell differentiation research and for the creation of induced pluripotent stem (iPS) cell lines.⁸ MSCs have also found applications in tissue engineering,³,⁵,¹¹,¹⁴ cell therapy,¹² and regenerative medicine.⁶,⁷,⁹,¹⁰

0%

20%

40%

60%

80%

100%

120%

CD29 CD44 CD73 CD90 CD105 CD166 CD14 CD31 CD34 CD45

Surface Antigen

Perc

ent

Cells

Pos

itiv

e

Figure 2: ATCC Pr im ar y Cell S olution s adipose-derived mesenchymal stem cells were taken from liquid nitrogen and cultures initiated. A sample for analysis by flow cytometry was taken when the culture was initiated and then after 48-hours of growth. The cells must test positive for CD29, CD44, CD73, CD90, CD105, and CD166 (greater than 95% of the cell population expresses these markers by flow cytometry). The cells must test negative for CD14, CD31, CD34, and CD45 (less than 2% of cell population expresses these markers by flow cytometry).

Fresh from Cryo 48 Hours Growth

Adipose-Derived Mesenchymal Stem Cells; Normal, Human (ATCC PCS-500-011).







Mesenchymal Stem Cells Growth Kit Options Basal Medium

Adipose-Derived Mesenchymal Stem Cells; Normal, Human (ATCC PCS-500-011)

Mesenchymal Stem Cell Growth Kit-Low Serum(ATCC PCS-500-040)

Mesenchymal Stem Cell Basal Medium (ATCC PCS-500-030)

Umbilical Cord-Derived Mesenchymal Stem Cells; Normal, Human (ATCC PCS-500-010)

Mesenchymal Stem Cells, Bone-Marrow Derived; Normal, Human (ATCC PCS-500-012)

Subcutaneous Pre-adipocytes; Normal, Human (ATCC PCS-210-010) Fibroblast Growth Kit-Low Serum (ATCC PCS-201-041)

Fibroblast Basal Medium (ATCC PCS-201-030)





PREPARATION OF COMPLETE GROWTH MEDIA1 Obtain 1 Mesenchymal Stem Cell Growth Kit–Low Serum from the freezer; make sure that the caps of all components are tight.

2 Thaw the components of the growth kit just prior to adding them to the basal medium.

3 Obtain 1 bottle of Mesenchymal Stem Cell Basal Medium from cold storage.



Table 15: Mesenchymal Stem Cell Growth Kit–Low Serum (ATCC PCS-500-040)


MSC Supplement 10 mL

2% FBS5 ng/mL rh FGF basic5 ng/mL rh FGF acidic5 ng/mL rh EGF

L-Alanyl-L-Glutamine 6 mL 2.4 mM


7 Complete growth media should be stored in the dark at 2°C to 8°C (do not freeze). When stored under these conditions, complete growth media is stable for 2 weeks.


cells recovered from each lot of ATCC Human Mesenchymal Stem Cells.



4 While the culture flasks equilibrate, remove 1 vial of ATCC Human Mesenchymal Stem Cells from storage and thaw the cells by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 1 to 2 minutes).























5 After 24 to 48 hours, view each flask under the microscope to determine percent cellular confluence. If not ready to passage, repeat steps 3 and 4 as described above. When cultures have reached approximately 70% to 80% confluence, and are actively proliferating (many mitotic figures are visible), it is time to subculture.

SUBCULTURE1 Passage normal mesenchymal stem cells when the culture has reached approximately 70% to 80% confluence.














15 Count the cells and seed new culture flasks at a density of 5,000 viable cells per cm².


A D I P O S E - D E R I V E D M E S E N C H Y M A L S T E M C E L L D I F F E R E N T I AT I O N P R O T O C O L SADIPOCY TE DIFFERENTIATION

MATERIALS NEEDED

The Adipocyte Differentiation Toolkit (ATCC PCS-500-050) contains medium and reagents designed to induce adipogenesis in actively proliferating Adipose-Derived Mesenchymal Stem Cells (ATCC PCS-500-011) with high efficiency, and support maturation of derived adipo-cytes during lipid accumulation.

PREPARING CELLS FOR ADIPOCY TE DIFFERENTIATION1 Follow the instructions for the growth of Adipose-Derived Mesenchymal Stem Cells (ATCC PCS-500-011). It is recommended that

the cells not be passaged more than four (4) times before initiating adipocyte differentiation.

2 When cells are 70-80% confluent, passage them into a tissue culture plate at a density of 18,000 cells/ cm². Adjust the number of cells and volume of media according to the tissue culture plate used.

NOTE:

Adipose- and umbilical cord-derived stem cells are contact inhibited. It is essential that the cells be subcultured BEFORE reaching confluence as post-confluent cells exhibit changes in morphology, slower proliferation, and reduced differ-entiation capacity after passaging.










Example: For a 6-well tissue culture plate with a surface area of 9.5 cm²/well, add a total of 171,000 viable cells to each well contain-ing 2 mL of Mesenchymal Stem Cell Basal Medium (ATCC PCS-500-030) supplemented with Mesenchymal Stem Cell Growth Kit–Low Serum (ATCC PCS-500-040) components.

3 Gently rock the plate back and forth and side to side to evenly distribute cells before incubation. Do not swirl.

4 Incubate the cells at 37°C with 5% CO₂ for 48 hours before initiating adipocyte differentiation.

ADIPOCY TE DIFFERENTIATION MEDIA PREPARATION

The adipocyte differentiation process requires two separate media preparations: one for initiation and one for maintenance. Stock solu-tions of these media can be prepared in tandem in advance as follows:

1 Thaw all three components of the differentiation kit and warm to 37°C in a water bath.

2 Decontaminate the external surfaces of all three kit components by spraying them with 70% ethanol.

3 Using aseptic technique and working in a laminar flow hood or biosafety cabinet:

a Transfer 15 mL of Adipocyte Basal Medium and 1 mL of AD Supplement to a sterile 50 mL conical tube, using a separate sterile pipette for each transfer. This is your working stock of Adipocyte Differentiation Initiation Medium used during the first 96 hours of differentiation.

b Add 5 mL of ADM Supplement to the remaining 85 mL of Adipocyte Basal Medium. This is your working stock of Adipocyte Differentiation Maintenance Medium.

4 Tightly cap the each container of media and swirl the contents gently to assure a homogeneous solution. Do not shake forcefully to avoid foaming. Label and date the bottle.

5 Each container of differentiation medium should be stored in the dark at 2°C to 8°C (do not freeze). When stored under these conditions, the differentiation media is stable for up to three weeks.

ADIPOCY TE DIFFERENTIATION PROCEDURE A Initiation Phase

1 After incubating the prepared Adipose-Derived Mesenchymal Stem Cells for (as described above), carefully aspirate the media from the wells.

2 Immediately rinse the cells once by adding 2 mL of room-temperature D-PBS (ATCC 30-2200) to each well, then carefully aspirate the PBS from the wells.

3 Add 2 mL of pre-warmed (37°C) Adipocyte Differentiation Initiation Medium to each well to begin the adipocyte differentiation process.

4 Incubate the cells at 37°C with 5% CO₂ for 48 hours.

5 Feed the cells by carefully removing half the volume of media (1 mL) from each well and adding another 2 mL of pre-warmed (37°C) Adipocyte Differentiation Initiation Medium to each well.

Important: DO NOT TILT plate during aspiration. It is important that the cell monolayer is not exposed to air during this and subsequent steps to ensure that developing lipid vesicles do not burst.

B Maintenance Phase

6 Incubate the cells at 37°C with 5% CO₂ for 48 hours.

7 Carefully remove 2 mL of media from each well (leaving 1 mL) and replace with 2 mL of pre-warmed (37°C) Adipocyte Differentiation Maintenance Medium in each well.

Important: DO NOT TILT plate during aspiration. It is important that the cell monolayer is not exposed to air during this and subsequent steps to ensure that developing lipid vesicles do not burst.

8 Repeat Steps 6 and 7 every 3-4 days for another 11 days until adipocytes reach full maturity. (Full maturity will be reached 15 days after the beginning of initiation phase, or 17 days from initial plating of cells.)

9 Cells can be used at any phase of adipocyte differentiation as predicated upon experimental design. To confirm lipid accumulation, cells can be fixed and stained with Oil Red O.

Additional differentiation protocols, including Chondrocyte and Osteocyte differentiation of Adipose-derived Mesenchymal Stem Cells, are available online at www.atcc.org.

NOTE:

It may be necessary to shake the AD Supplement and the ADM Supplement upon warming to help re-dissolve any components that may have precipitated out of solution upon freezing.

NOTE:

It is recommended that you transfer the required volume of media to a sterile tube for pre-warming prior to each feed-ing rather than repeatedly re-warming the entire working stock.

Adipocytes differentiated from Adipose-derived Mesenchymal Stem Cells (ATCC PCS-500-011) and stained with Oil Red O to detect the formation of lipid droplets.




http://www.atcc.org



REFERENCES 1 Stein GS, et al. Human Stem Cell Technology and Biology: A Research Guide and Laboratory Manual. Wiley & Sons, Hoboken, New

Jersey, 2011.

2 Zuk PA, et al. Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies. Tissue Eng. 7(2):211-228), 2001.

3 Zuk PA, et al. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell. 13:4279-4295, 2002.

4 Ogawa R. The Importance of Adipose-Derived Stem Cell and Vascularized Tissue Regeneration in the Field of Tissue Transplantation. Cur. Stem Cell Res. 1:13-20, 2006.

5 Shaeffler A & Buechler C. Concise review: adipose tissue-derived stromal cells—basic and clinical applications for novel cell-based therapies. Stem Cells 25:818-827, 2007.

6 Kang SK, et al. Neurogenesis of Rhesus adipose stromal cells. J. Cell Sci. 117:4289-4299, 2004.

7 Safford KM, et al. Stem cell therepy for neurologic disorders: Therapeutic potential of adipose-derived stem cells. Current Drug Targets 6:57-62, 2005.

8 Safford KM, et al. Characterization of neuronal/glial differentiation of murine adipose-derived adult stromal cells. Exp. Neurol. 187:319-328, 2004.

9 Kingham PJ, et al. Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. Exp. Neurol. 207:267-274, 2007.

10 Xu, et al. Myelin-forming ability of Schwann cell-like cells induced from rat adipose-derived stem cells in vitro. Brain Res. 1239:49-55, 2008.

11 Seo MJ, et al. Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem. Biophys. Res. Commun. 328:258-264, 2005.

12 Timper K, et al. Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochem. Biophys. Res. Commun. 341:1135-1140, 2006.

13 Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315-317, 2006.

14 Freshney, RI. Culture of Animal Cells: A Manual of Basic Technique, 6th Ed. John Wiley & Sons, Hoboken, New Jersey, 2010.

15 Histology Text Atlas Book. Chapter 3: Connective Tissue. Downloaded from Visual Histology.com at http://www.visualhistology.com/products/atlas/VHA_Chpt3_Connective_Tissue.html on March 26, 2012.

16 Elias JA, et al. Regulation of Human Lung Fibroblast Glycosaminoglycan Production by Recombinant Interferons, Tumor Necrosis Factor, and Lymphotoxin. J. Clin. Invest. 81:325-333, 1988.

17 Rieger MM. Keratinocyte function and skin health. Cosmetics and Toiletries, July 01, 1992. Downloaded on March 26, 2012 from Access My Library at http://www.accessmylibrary.com/article/print/1G1-12484573.

18 Bensouilah J, et al. Aromadermatology: Aromatherapy in the Treatment and Care of Common Skin Conditions. Blackwell Publishers, 2006. Chapter 1 downloaded on March 26, 2012 at http://courses.washington.edu/bioen327/Labs/Lit_SkinStruct_Bensouillah_Ch01.pdf.

Have Questions?

Search ATCC Frequently Asked Questions online at www.atcc.org for answers related to primary cells, or contact ATCC Technical Services at [email protected] for additional information.

Page 30 Order online at www.atcc.org, call 800.638.6597, 703.365.2700, or contact your local distributor. Page 31Order online at www.atcc.org, call 800.638.6597, 703.365.2700, or contact your local distributor.

Table 16: ATCC Primary Cells and Needed ReagentsAll of these ATCC primary cells products are human species and require the following reagents: Phenol Red (ATCC PCS-999-001); D-PBS (ATCC 30-2200); Trypsin-EDTA for Primary Cells (ATCC PCS-999-003); Trypsin Neutralizing Solution (ATCC PCS-999-004).

Product Name (ATCC number) Applications

Number of viable cells-post thaw

Passage at freezing

Cells tested upon thaw to achieve Basal media Growth kit Additional Reagents

Endothelial CellsUmbilical Vein Endothelial Cells; Normal, Human (PCS-100-010) Physiological and pharmacological investigations, such as macromolecule transport, blood

coagulation, angiogenesis, and fibrinolysis≥5.0 x 10⁵ 1 ≥15 PDL

Vascular Cell Basal Medium (PCS-100-030) Endothelial Cell Growth Kit-BBE (PCS-100-040) or Endothelial Cell Growth Kit-VEGF (PCS-100-041)

Not applicable

Umbilical Vein Endothelial Cells; Normal, Human, Pooled (PCS-100-013) ≥5.0 x 10⁵ 2 ≥15 PDL

Aortic Endothelial Cells; Normal, Human (PCS-100-011)Studies of vascular diseases such as thrombosis, atherosclerosis, metabolism, and hypertension, stent-graft compatibility testing, and membrane conductance models

≥5.0 x 10⁵ 2 ≥15 PDL

Coronary Artery Endothelial Cells; Normal, Human (PCS-100-020) ≥5.0 x 10⁵ 3 ≥15 PDL

Pulmonary Artery Endothelial Cells; Normal, Human (PCS-100-022) ≥5.0 x 10⁵ 3 ≥15 PDL

Dermal Microvascular Endothelial Cells; Normal, Human, Neonatal (PCS-110-010) Studies of microvascular functions and cutaneous inflammation ≥5.0 x 10⁵ 3 ≥15 PDL Vascular Cell Basal Medium (PCS-100-030) Microvascular Endothelial Cell Growth Kit-BBE (PCS-110-040) or

Microvascular Endothelial Cell Growth Kit-VEGF (PCS-110-041)

Smooth Muscle CellsAortic Smooth Muscle Cells; Normal, Human (PCS-100-012)

Studies of vascular diseases, such as thrombosis and atherosclerosis

≥5.0 x 10⁵ 2 ≥15 PDL

Vascular Cell Basal Medium (PCS-100-030) Vascular Smooth Muscle Cell Growth Kit (PCS-100-042) Not applicable

Coronary Artery Smooth Muscle Cells; Normal, Human (PCS-100-021) ≥5.0 x 10⁵ 2 ≥15 PDL

Pulmonary Artery Smooth Muscle Cells; Normal, Human (PCS-100-023) ≥5.0 x 10⁵ 2 ≥15 PDL

Lung Smooth Muscle Cells; Normal, Human (PCS-130-010) ≥5.0 x 10⁵ 2 >15 PDL

Bronchial/Tracheal Smooth Muscle Cells; Normal, Human (PCS-130-011) ≥5.0 x 10⁵ 2 >15 PDL

Bladder Smooth Muscle Cells; Normal, Human (PCS-420-012) ≥5.0 x 10⁵ 2 >15 PDL

Uterine Smooth Muscle Cells; Normal, Human (PCS-460-010) ≥5.0 x 10⁵ 2 >15 PDL

Epithelial Cells

Small Airway Epithelial Cells; Normal, Human (PCS-301-010) Asthma, airway inflammation, and wound healing, pulmonary fibrosis, COPD, cancer, toxicology, intracellular pH regulations, IL-1b effect to stimulate airway epithelial cell growth, and ICAM-1 expression

≥5.0 x 10⁵ 1 ≥15 PDL Airway Epithelial Cell Basal Medium (PCS-300-030)

Small Airway Epithelial Cell Growth Kit (PCS-301-040) or Bronchial Epithelial Cell Growth kit (PCS-300-040)

Not applicable

Bronchial/Tracheal Epithelial Cells; Normal, Human (PCS-300-010) ≥5.0 x 10⁵ 1 ≥15 PDL

Lobar Bronchial Epithelial Cells; Normal, Human (PCS-300-015)Asthma, airway inflammation, and wound healing, pulmonary fibrosis, COPD, cancer, toxicology, intracellular pH regulations, IL-1b effect to stimulate airway epithelial cell growth, and ICAM-1 expression

≥5.0 x 10⁵ 1 >10 PDL Airway Epithelial Cell Basal Medium (PCS-300-030) Bronchial Epithelial Cell Growth Kit (PCS-300-040)

Renal Proximal Tubule Epithelial Cells; Normal, Human (PCS-400-010) In vitro studies of osmoregualtion and excretion, renal fibrosis, inflammation, as well as applications in drug screening/development, eg, hypertension, diabetes, oncology, autoimmune disease, and toxicology screening

≥5.0 x 10⁵ 2 ≥15 PDLRenal Epithelial Cell Basal Medium (PCS-400-030) Renal Epithelial Cell Growth Kit (PCS-400-040)Renal Cortical Epithelial Cells; Normal, Human (PCS-400-011) ≥5.0 x 10⁵ 1 ≥15 PDL

Renal Mixed Epithelial Cells; Normal, Human (PCS-400-012) ≥5.0 x 10⁵ 1 ≥15 PDL

Bladder Epithelial Cells (A/T/N); Normal, Human (PCS-420-010) Incontinence and reconstruction studies or development of a potential diagnostic method for the early detection of bladder cancer cells ≥5.0 x 10⁵ 2 >15 PDL Bladder Epithelial Basal Medium (PCS-420-032) Bladder Epithelial Growth Kit (PCS-420-042)

Prostate Epithelial Cells; Normal, Human (PCS-440-010) Hormonal regulation of the prostate, the secretory function of prostate cells, and prostate cancer ≥5.0 x 10⁵ 2 ≥15 PDL Prostate Epithelial Cell Basal Medium

(PCS-440-030) Prostate Epithelial Cell Growth Kit (PCS-440-040)

Vaginal Epithelial Cells; Normal, Human (PCS-480-010) Cancer studies, microbiological organism to cell interaction, toxicity studies ≥5.0 x 10⁵ 3 >10 PDL Vaginal Epithelial Basal Medium (PCS-480-030) Vaginal Epithelial Growth Kit (PCS-480-040)

Cervical Epithelial Cells; Normal, Human (PCS-480-011) Pathophysiology of cervical polyps, HPV, and cervical cancer ≥5.0 x 10⁵ 3 >10 PDL Cervical Epithelial Cell Basal Medium (PCS-480-032) Cervical Epithelial Cell Growth Kit (PCS-480-042)

Mammary Epithelial Cells; Normal, Human (PCS-600-010) Breast cancer development, and 3-D culture and carcinogen screening ≥5.0 x 10⁵ 3 >15 PDL Mammary Epithelial Cell Basal Medium (PCS-600-030) Mammary Epithelial Cell Growth Kit (PCS-600-040)

Corneal Epithelial Cells; Normal, Human (PCS-700-010) Cell de-differentiation, toxicology testing, and drug development ≥5.0 x 10⁵ 2 3 passages Corneal Epithelial Cell Basal Medium (PCS-700-030) Corneal Epithelial Cell Growth Kit (PCS-700-040)

Fibroblasts

Dermal Fibroblasts; Normal, Human Neonatal (PCS-201-010) Wound healing studies, tissue engineering and regeneration applications, as well as induction of pluripotent stem (iPSCs) ≥5.0 x 10⁵ 1 ≥10 PDL in

serum-free medium

Fibroblast Basal Medium (PCS-201-030) Fibroblast Growth Kit–Serum-Free (PCS-201-040) or Fibroblast Growth Kit–Low Serum (PCS-201-041)

0.1% Gelatin Solution (PCS-999-027) only for use with Mitomicin C treated Dermal Fibroblasts

Dermal Fibroblasts; Normal, Human Adult (PCS-201-012) Wound healing studies, tissue engineering and regeneration applications, as well as induction of pluripotent stem (iPSCs) ≥5.0 x 10⁵ 1 ≥10 PDL in

serum-free medium

Lung Fibroblasts; Normal, Human (PCS-201-013) Lung disorders and infections, lung reconstruction studies, and advancement of cancer research ≥5.0 x 10⁵ 2 >15 PDL

Not applicableGingival Fibroblasts; Normal, Human (PCS-201-018) Regenerative medicine studies, alternate source of MSCs ≥5.0 x 10⁵ 2 >15 PDL

Bladder Fibroblasts; Normal, Human (PCS-420-013) Detection of bladder cancer cells, reconstruction studies, and advancement of cancer research ≥5.0 x 10⁵ 2 >15 PDL

Uterine Fibroblast; Normal, Human (PCS-460-010) Research related to female reproductive biology, drug testing, and oncology ≥5.0 x 10⁵ 2 >15 PDL

KeratinocytesEpidermal Keratinocytes; Normal, Human, Neonatal Foreskin (PCS-200-010) Studies of growth factor activity, wound healing, toxicity/irritancy studies, and use as target

cells for derivation of induced pluripotent stem cells≥5.0 x 10⁵ 1 ≥15 PDL

Dermal Cell Basal Medium (PCS-200-030) Keratinocyte Growth Kit (PCS-200-040) Not applicableEpidermal Keratinocytes; Normal, Human, Adult (PCS-200-011) ≥5.0 x 10⁵ 1 ≥15 PDL

Gingival Keratinocytes; Normal, Human (PCS-200-014) Antibiotic treatment, dental implants, and many other applications for oral biology research ≥5.0 x 10⁵ 2 >15 PDL

MelanocytesEpidermal Melanocytes; Normal, Human, Neonatal Foreskin (PCS-200-012) Wound healing, testing models for toxicity/irritancy studies, melanoma, dermal response to

UV radiation, psoriasis and other skin diseases, and cosmetic research ≥5.0 x 10⁵ 2 ≥15 PDL

Dermal Cell Basal Medium (PCS-200-030) Melanocyte Growth Kit (PCS-200-041) Not applicableEpidermal Melanocytes; Normal, Human, Adult (PCS-200-013) ≥5.0 x 10⁵ 2 ≥15 PDL

Mesenchymal Stem CellsUmbilical Cord-Derived Mesenchymal Stem Cells; Normal, Human (PCS-500-010)

Adult stem cell differentiation research, induced pluripotent stem cell lines, tissue engineering, cell therapy, and regenerative medicine

≥5.0 x 10⁵ 2 ≥10 PDL

Mesenchymal Stem Cell Basal Medium (PCS-500-030)

Mesenchymal Stem Cell Growth Kit-Low Serum (PCS-500-040)

Adipocyte Differentiation Tool (PCS-500-050)

Chondrocyte Differentiation Tool (PCS-500-051) Adipose-Derived Mesenchymal Stem Cells; Normal, Human (PCS-500-011) ≥1.0 x 10⁶ 2 ≥10 PDL

Osteocyte Differentiation Tool (PCS-500-052)

Bone Marrow-Derived Mesenchymal Stem Cells; Normal, Human (PCS-500-012)

Useful as an in vitro model for the study of multipotent stem cell biology, differentiation, and regenerative medicine and tissue engineering ≥1.0 x 10⁶ 2 ≥10 PDL Mesenchymal Stem Cell Growth Kit for Bone Marrow MSCs

(PCS-500-041)Adipocyte Differentiation Toolkit for BM-MSCs (PCS-500-053)

Primary Subcutaneous Preadipocytes; Normal, Human (PCS-210-010) Differentiation research, tissue engineering, cell therapy, and regenerative medicine ≥1.0 x 10⁶ 2 ≥15 PDL Fibroblast Basal Medium (PCS-201-030)

Fibroblast Growth Kit–Low Serum (PCS-201-041)

Adipocyte Differentiation Tool (PCS-500-050)

Skeletal Muscle Cells

Skeletal Muscle Cells; Normal, Human (PCS-950-010) Ideal culture model for the study of muscle cell biology, diabetes, insulin receptor studies, muscle cell metabolism, muscle tissue repair, and myotube development ≥5.0 x 10⁵ 3 >10 PDL Mesenchymal Stem Cell Basal Medium

(PCS-500-030) Skeletal Muscle Growth Kit (PCS-950-040) Skeletal Muscle Differentiation Tool (PCS-950-050)



















http://PCS-130-011







































































PC-012022-v03

©2022 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection unless indicated otherwise. Vi-Cell® is a registered trademark of Beckman Coulter.

These products are for laboratory use only. Not for human or diagnostic use. ATCC products may not be resold, modified for resale, used to provide commercial services, or to manufacture commercial products without prior ATCC written approval.

703.365.2700

703.365.2701

[email protected]

www.atcc.org

10801 University Boulevard Manassas, Virginia 20110-2209

Documents

tips and techniques for culturing primary cells